Angiotensin-(1-9) Improves the Cardioprotective Effects of Del Nido Cardioplegia Against Ischemia/Reperfusion Injury

Evelyn Mendoza-Torres1, Gina Sanchez2, Wendy Rosales1

  • 1Grupo de Investigación Avanzada en Biomedicina, Faculty of Health, Exact and Natural Sciences, Universidad Libre Seccional Barranquilla, Barranquilla, Colombia.

Insights

Del Nido cardioplegia (DNC) combined with Angiotensin-(1-9) (Ang-(1-9)) and Angiotensin-(1-7) (Ang-(1-7)) reduced heart cell damage during simulated ischemia/reperfusion. Ang-(1-9) also improved recovery of heart function and reduced arrhythmias in rat hearts.

Area of Science:

  • Cardiology
  • Cardiovascular Surgery
  • Biochemistry

Background:

  • Del Nido cardioplegia (DNC) is a standard solution for inducing cardiac arrest during surgery.
  • Ischemia/reperfusion (I/R) injury remains a significant concern in cardiac procedures.
  • Angiotensin peptides, Angiotensin-(1-9) (Ang-(1-9)) and Angiotensin-(1-7) (Ang-(1-7)), show potential cardioprotective effects.

Purpose of the Study:

  • To investigate the cardioprotective effects of Ang-(1-9) and Ang-(1-7) as adjuvants to DNC.
  • To evaluate their impact on ventricular function and I/R injury in isolated rat hearts and cultured cardiomyocytes.

Main Methods:

  • Isolated rat hearts and cultured neonatal rat ventricular myocytes were subjected to I/R and simulated I/R (sI/R).
  • Hearts and myocytes were treated with DNC alone or DNC combined with Ang-(1-9) and/or Ang-(1-7).
  • Lactate dehydrogenase (LDH) release, arrhythmias, and left ventricular developed pressure were measured.

Main Results:

  • DNC with Ang-(1-9) and Ang-(1-7) significantly decreased LDH release in sI/R-exposed cardiomyocytes.
  • Hearts reperfused with DNC and Ang-(1-9) showed fewer arrhythmias.
  • Ang-(1-9) treatment expedited left ventricular developed pressure stability post-I/R.

Conclusions:

  • Ang-(1-9) and Ang-(1-7) enhance the cardioprotective properties of DNC.
  • Ang-(1-9) as an adjuvant to DNC improves ventricular function recovery and reduces arrhythmias after I/R injury.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
374
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
460
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
474
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
573
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
504
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
507